New product newswire: February 2, 2006

The company’s investigational ABCWY vaccine candidate will be reviewed by the FDA by February 14, 2025.

Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.

Fasenra was initially approved in 2017 as an add on maintenance therapy in patients aged 12 years and older.

The antibiotic was approved to treat Staphylococcus aureas bacteremia, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia.

The drug was previously approved in 2009 to treat schizophrenia.

Rejoyn from Otsuka Pharmaceutical and Click Therapeutics is a 6-week program that helps enhance cognitive control of emotions through brief therapy lessons and training exercises.